Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:24 2024-07-05 EDT			5-day change	1st Jan Change
90.94 ^EUR	-0.07%		+1.20%	+1.31%

07-05	Sector Update: Health Care Stocks Steady Premarket Friday	MT
07-05	Sector Update: Health Care	MT

SANOFI : Berenberg reiterates its Buy rating

July 03, 2024 at 09:05 am

In a research note published by Luisa Hector, Berenberg advises its customers to buy the stock. The target price continues to be set at EUR 105.

Latest news about Sanofi

Sector Update: Health Care Stocks Steady Premarket Friday	07-05	MT
Sector Update: Health Care	07-05	MT
GlaxoSmithkline Pharmaceuticals Limited Announces Change in Management	07-05	CI
Sanofi's Consumer Health Unit Receives Interest from French State	07-04	MT
Bpifrance eyes investment in Sanofi's consumer health business	07-04	RE
Bain Capital, Cinven, Others Said Mulling Bids for Sanofi's Consumer Health Unit	07-04	MT
Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports	07-04	DJ
Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency	07-03	MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division	07-03	MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division	07-03	MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division, Bloomberg Reports	07-03	MT
SANOFI : Berenberg reiterates its Buy rating	07-03	ZD
SANOFI : JP Morgan remains Neutral	07-03	ZD
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits	07-03	MT
Sanofi Blockbuster Drug Dupixent Gets First-in-World Approval in Europe for COPD	07-03	MT
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval	07-03	MT
Sanofi: approval of Dupixent for COPD in the EU	07-03	CF
Sanofi obtains EU approval for Dupixent	07-03	RE
Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease	07-03	DJ
Sanofi Wins EU Nod for Dupixent as Add-on Treatment for Chronic Obstructive Pulmonary Disease	07-03	MT
EU approves Sanofi's Dupixent for 'smoker's lungs'	07-03	RE
SANOFI SAYS DUPIXENT GRANTED EUROPEAN UNION APPROVAL TO TREAT…	07-03	RE
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD	07-03	CI
Top Midday Stories: Tesla, GM Report Vehicle Deliveries; Biden, Sanders Say Novo Nordisk, Eli Lilly Charge 'Unconscionably' High Prices; Warner Bros. Interested in Deal With Paramount	07-02	MT
SANOFI : Jefferies reaffirms its Buy rating	07-02	ZD

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

CAC 40 , Euro STOXX 50 Index , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency

July 03, 2024 at 04:01 pm

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 07:58 am

Sanofi : In the hot seat

October 30, 2023 at 06:52 am

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

90.94 EUR

Average target price

108.1 EUR

Spread / Average Target

+18.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	+1.31%	123B
ELI LILLY AND COMPANY	+56.89%	809B
NOVO NORDISK A/S	+39.52%	624B
JOHNSON & JOHNSON	-6.55%	351B
ABBVIE INC.	+7.92%	289B
ASTRAZENECA PLC	+13.74%	240B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	166B
PFIZER, INC.	-2.57%	157B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : Berenberg reiterates its Buy rating

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals